$3.65 Billion is the total value of Rock Springs Capital Management LP's 143 reported holdings in Q2 2020. The portfolio turnover from Q1 2020 to Q2 2020 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NVAX | New | NOVAVAX INC | $47,559,000 | – | 570,598 | +100.0% | 1.30% | – |
| RPRX | New | ROYALTY PHARMA PLC | $24,275,000 | – | 500,000 | +100.0% | 0.67% | – |
| ALXN | New | ALEXION PHARMACEUTICALS INC | $20,596,000 | – | 183,500 | +100.0% | 0.56% | – |
| FUSN | New | FUSION PHARMACEUTICALS INC | $16,370,000 | – | 937,041 | +100.0% | 0.45% | – |
| New | GOSSAMER BIO INCnote 5.000% 6/0 | $15,746,000 | – | 15,573,000 | +100.0% | 0.43% | – | |
| TGTX | New | TG THERAPEUTICS INC | $13,303,000 | – | 682,926 | +100.0% | 0.36% | – |
| BFAM | New | BRIGHT HORIZONS FAM SOL IN D | $11,544,000 | – | 98,500 | +100.0% | 0.32% | – |
| SWAV | New | SHOCKWAVE MED INC | $9,356,000 | – | 197,500 | +100.0% | 0.26% | – |
| LEGN | New | LEGEND BIOTECH CORPsponsored ads | $8,763,000 | – | 205,896 | +100.0% | 0.24% | – |
| RPTX | New | REPARE THERAPEUTICS INC | $8,525,000 | – | 274,815 | +100.0% | 0.23% | – |
| BLU | New | BELLUS HEALTH INC NEW | $7,163,000 | – | 696,115 | +100.0% | 0.20% | – |
| IGMS | New | IGM BIOSCIENCES INC | $6,955,000 | – | 95,278 | +100.0% | 0.19% | – |
| BNR | New | BURNING ROCK BIOTECH LTDsponsored ads | $5,402,000 | – | 200,000 | +100.0% | 0.15% | – |
| NARI | New | INARI MED INC | $3,875,000 | – | 80,000 | +100.0% | 0.11% | – |
| CYTK | New | CYTOKINETICS INC | $1,825,000 | – | 77,417 | +100.0% | 0.05% | – |
| New | NEVRO CORPnote 2.750% 4/0 | $683,000 | – | 500,000 | +100.0% | 0.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-08-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
| NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
| ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
| ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
| INVITAE CORP | 35 | Q3 2023 | 1.8% |
| BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
| MACROGENICS INC | 35 | Q3 2023 | 0.5% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
| Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
| Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
| PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
| Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
| FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
| Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.